Efficacy of Dopamine Agonists (Cabergoline vs Bromocriptine) in Galactorrhea–Amenorrhea Syndrome
Article Sidebar
Main Article Content
Abstract
Galactorrhea-amenorrhea syndrome is a condition caused by hyperprolactinemia where inappropriate milk secretion and menstrual irregularities are seen. GAS is known to have considerable physiological, reproductive, and social impact on women suffering from this disease. Dopaminergic drugs such as cabergoline and bromocriptine are considered the core treatment options for this condition. The objective of this research is to perform an elaborate comparison between the effectiveness and safety of cabergoline and bromocriptine using an analysis of various randomized controlled trials, observational studies, and meta-analyses. The results indicate that cabergoline not only demonstrates better effectiveness in normalizing prolactin levels but also offers ovulatory menses and absence of galactorrhea. Furthermore, cabergoline has better tolerability and safety.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
How to Cite
References
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011). Diagnosis and treatment of hyperprolactinemia. Journal of Clinical Endocrinology & Metabolism, 96(2), 273–288.
https://doi.org/10.1210/jc.2010-1692
Ben-Jonathan, N., & Hnasko, R. (2001). Dopamine as a prolactin inhibitor. Endocrine Reviews, 22(6), 724–763.
https://doi.org/10.1210/edrv.22.6.0451
Biller, B. M. K., Luciano, A., Crosignani, P. G., Molitch, M.,
Olive, D., Rebar, R., & Webster, J. (1996). Guidelines for the diagnosis and treatment of hyperprolactinemia. New England Journal of Medicine, 335(18), 1389–1394.
https://doi.org/10.1056/NEJM199611073351907
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994). A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine, 331(14), 904–909.
https://doi.org/10.1056/NEJM199410063311403
Colao, A., Lombardi, G., & Annunziato, L. (2000). Cabergoline. Journal of Clinical Endocrinology & Metabolism, 85(6), 2247–2252.
https://doi.org/10.1210/jcem.85.6.6668
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006). Advances in the treatment of prolactinomas. Endocrine Reviews, 27(5), 485–534. https://doi.org/10.1210/er.2005-9998
Verhelst, J., Abs, R., Maiter, D., Van den Bruel, A.,
Vandeweghe, M., Velkeniers, B., & Mockel, J. (1999). Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. Journal of Clinical Endocrinology & Metabolism, 84(7), 2518–2522.
https://doi.org/10.1210/jcem.84.7.5816
Wang, A. T., Mullan, R. J., Lane, M. A., Hazem, A., Prasad, K., Gathaiya, N. W., & Montori, V. M. (2012). Treatment of hyperprolactinemia: A systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism, 97(7), 237–245.
https://doi.org/10.1210/jc.2012-2178
Dos Santos Nunes, V., El Dib, R., Boguszewski, C. L., &
Nogueira, C. R. (2011). Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: A systematic review. Clinical Endocrinology, 75(4), 532–538. https://doi.org/10.1111/j.1365-2265.2011.04096.x
Greenman, Y., & Stern, N. (2009). Optimal therapy for prolactinomas. Clinical Endocrinology, 70(1), 7–15. https://doi.org/10.1111/j.1365-2265.2008.03476.x
Di Sarno, A., Landi, M. L., Marzullo, P., Di Somma, C.,
Pivonello, R., Cerbone, G., & Colao, A. (2001). Predictors of remission after long-term cabergoline therapy. Journal of Clinical Endocrinology & Metabolism, 86(8), 3574–3579. https://doi.org/10.1210/jcem.86.8.7727
Molitch, M. E. (2014). Management of medically refractory prolactinoma. Journal of Neuro-Oncology, 117(3), 421–428.
https://doi.org/10.1007/s11060-013-1349-5
Schlechte, J. A. (2003). Long-term management of prolactinomas. Endocrinology and Metabolism Clinics of North America, 32(3), 585–594. https://doi.org/10.1016/S0889-8529(03)00032-7
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R.,
Bonert, V., Bronstein, M. D., & Giustina, A. (2006). Guidelines of the Pituitary Society for prolactinomas. Clinical Endocrinology, 65(2), 265–273. https://doi.org/10.1111/j.1365-2265.2006.02562.x
Maiter, D., & Delgrange, E. (2014). Therapy of endocrine disease: Prolactinoma. European Journal of Endocrinology, 170(5), R213–R223.
https://doi.org/10.1530/EJE-13-0974
Maiter, D., & Tichomirowa, M. A. (2013). Epidemiology of prolactinomas. Pituitary, 16(2), 153–160. https://doi.org/10.1007/s11102-012-0396-1
Vilar, L., Vilar, C. F., Lyra, R., & Lyra, R. (2019). Pitfalls in the diagnostic evaluation of hyperprolactinemia. Endocrine, 65(1), 123–131. https://doi.org/10.1007/s12020-019-01936-6
Colao, A., & Savastano, S. (2011). Medical treatment of prolactinomas. Nature Reviews Endocrinology, 7(5), 267–278.